Matrix metalloproteinases in the CNS: interferons get nervous.
Matrix metalloproteinases in the CNS: interferons get nervous. Cell Mol Life Sci. 2019 Jun 04;: Authors: Chopra S, Overall CM, Dufour A Abstract Matrix metalloproteinases (MMPs) have been investigated in context of chronic inflammatory diseases and demonstrated to degrade multiple components of the extracellular matrix (ECM). However, following several disappointing MMP clinical trials, recent studies have demonstrated unexpected novel functions of MMPs in viral infections and autoimmune inflammatory diseases in unanticipated locations. Thus, MMPs play additional functions in inflammation than just ECM degradation. They can regulate the activity of chemokines and cytokines of the immune response by precise proteolytic processing resulting in activation or inactivation of signaling pathways. MMPs have been demonstrated to cleave multiple substrates of the central nervous systems (CNS) and contribute to promoting and dampening diseases of the CNS. Initially, believed to be solely promoting pathologies, more than 10 MMPs to date have been shown to have protective functions. Here, we present some of the beneficial and destructive roles of MMPs in CNS pathologies and discuss strategies for the use of MMP inhibitors. PMID: 31165203 [PubMed - as supplied by publisher]
ABSTRACT Multiple sclerosis (MS) is an autoimmune, inflammatory, and degenerative disease of the central nervous system. Axonal degeneration is triggered by inflammation and is the pathological substrate of progressive disability in patients with MS. Therapeutic interventions can reduce inflammatory activity, thus delaying neurodegeneration and the progression of disability. Disease activity and neurodegeneration are assessed mainly through clinical evaluation and magnetic resonance imaging. These measures lack sensitivity and accuracy, so new biomarkers are necessary. Several markers have been studied and to date the most...
A new study finds that patients with autoimmune disease treated with anti- tumor necrosis factor alpha have an increased risk of developing inflammatory bowel disease.Medscape Medical News
MONDAY, July 15, 2019 -- Patients with autoimmune diseases have an increased risk for being diagnosed with Crohn disease (CD) or ulcerative colitis (UC) while under treatment with etanercept, according to a study published online July 2 in...
How does fatigue impact quality-of-life in patients with cutaneous lupus erythematosus and other skin-limited autoimmune diseases?The British Journal of Dermatology
Autoimmune Disease is the third most common disease type in the United States after cancer and heart disease. According to conventional medicine there is no cure for autoimmune disease. However,...(PRWeb July 15, 2019)Read the full story at https://www.prweb.com/releases/autoimmune_disease_facts_and_myths_six_fast_easy_and_economical_solutions_for_complete_recovery_that_your_doctor_doesn_t_know_about/prweb16424424.htm
ConclusionsThyroid hormone resistance continues to be an un(der)- and misdiagnosed thyroid condition whose management is particularly challenging when associated with autoimmune thyroid disease. Whole exome sequencing has the potential to identifyTHRB pathogenic variants as incidental findings. Reporting such secondary findings from genomic testing may be particularly important in the context of the rarity of the condition and the potential clinical consequences of misdiagnosis and mistreatment.
Conclusion: IgG4-related autoimmune disease should be considered in the diagnosis of patients who have tubulointerstitial nephritis with multisystem involvement. Further, mCRP autoantibodies may be associated with IgG4-related tubulointerstitial nephritis and might be useful as a diagnostic marker of the disease. PMID: 31296087 [PubMed - in process]
Authors: Finn SMB, Scheuermann U, Holzknecht ZE, Gao Q, Ibrahim MM, Parker W, Granek JA, Lin SS, McKenney EA, Barbas AS Abstract Aim: The aim of this study was to investigate the short-term effect of levofloxacin on the microbiota of healthy lungs. Material and methods: Male F344 rats received either no levofloxacin (n = 9), intravenous levofloxacin (n = 12), oral levofloxacin (n = 12), or subcutaneous levofloxacin (n = 14). Rats received a clinically applicable dose (5.56 mg/kg) of levofloxacin via the assigned delivery route once daily for three days....
Neuropsychopharmacology, Published online: 14 July 2019; doi:10.1038/s41386-019-0463-zSleep and neurological autoimmune diseases
Conclusion: Elevated blood and urinary ICAM-1 is a biomarker for SLE, but does not differentiate active and inactive SLE. PMID: 31298049 [PubMed - as supplied by publisher]